Skip to main content
Erschienen in: Surgery Today 2/2016

01.02.2016 | Review Article

Building a bridge to recovery: the pathophysiology of LVAD-induced reverse modeling in heart failure

verfasst von: Shigeru Miyagawa, Koichi Toda, Teruya Nakamura, Yasushi Yoshikawa, Satsuki Fukushima, Shunsuke Saito, Daisuke Yoshioka, Tetsuya Saito, Yoshiki Sawa

Erschienen in: Surgery Today | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Heart failure mainly caused by ischemic or dilated cardiomyopathy is a life-threatening disorder worldwide. The previous work in cardiac surgery has led to many excellent surgical techniques for treating cardiac diseases, and these procedures are now able to prolong the human lifespan. However, surgical treatment for end-stage heart failure has been under-explored, although left ventricular assist device (LVAD) implantation and heart transplantation are options to treat the condition. LVAD can provide powerful circulatory support for end-stage heart failure patients and improve the survival and quality of life after implantation compared with the existing medical counterparts. Moreover, LVADs play a crucial role in the “bridge to transplantation”, “bridge to recovery” and recently have served as “destination therapy”. The structural and molecular changes that improve the cardiac function after LVAD implantation are called “reverse remodeling”, which means that patients who have received a LVAD can be weaned from the LVAD with restoration of their cardiac function. This strategy is a desirable alternative to heart transplantation in terms of both the patient quality of life and due to the organ shortage. The mechanism of this bridge to recovery is interesting, and is different from other treatments for heart failure. Bridge to recovery therapy is one of the options in regenerative therapy which only a surgeon can provide. In this review, we pathophysiologically analyze the reverse remodeling phenomenon induced by LVAD and comment about the clinical evidence with regard to its impact on the bridge to recovery.
Literatur
1.
Zurück zum Zitat Alshammary S, et al. Impact of cardiac stem cell sheet transplantation on myocardial infarction. Surg Today. 2013;43(9):970–6.CrossRefPubMed Alshammary S, et al. Impact of cardiac stem cell sheet transplantation on myocardial infarction. Surg Today. 2013;43(9):970–6.CrossRefPubMed
2.
Zurück zum Zitat Akutsu T, Dreyer B, Kolff WJ. Polyurethane artificial heart valves in animals. J Appl Physiol. 1959;14:1045–8.PubMed Akutsu T, Dreyer B, Kolff WJ. Polyurethane artificial heart valves in animals. J Appl Physiol. 1959;14:1045–8.PubMed
3.
Zurück zum Zitat Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41(48):1271–4.PubMed Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41(48):1271–4.PubMed
4.
Zurück zum Zitat Rose EA, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.CrossRefPubMed Rose EA, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.CrossRefPubMed
5.
Zurück zum Zitat Birks EJ, et al. Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. J Thorac Cardiovasc Surg. 2012;144(1):190–6.CrossRefPubMed Birks EJ, et al. Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. J Thorac Cardiovasc Surg. 2012;144(1):190–6.CrossRefPubMed
6.
Zurück zum Zitat Zafeiridis A, et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98(7):656–62.CrossRefPubMed Zafeiridis A, et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98(7):656–62.CrossRefPubMed
7.
Zurück zum Zitat Ishimaru KMS, Fukushima S, Ide H, Hoashi T, Shibuya T, Ueno T, Sawa Y. Functional and pathological characteristics of reversible remodeling in a canine right ventricle in responce to volume overloading and volume unloading. Surg Today. 2014;44(10):11.CrossRef Ishimaru KMS, Fukushima S, Ide H, Hoashi T, Shibuya T, Ueno T, Sawa Y. Functional and pathological characteristics of reversible remodeling in a canine right ventricle in responce to volume overloading and volume unloading. Surg Today. 2014;44(10):11.CrossRef
8.
Zurück zum Zitat Razeghi P, et al. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology. 2003;100(1):17–22.CrossRefPubMed Razeghi P, et al. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology. 2003;100(1):17–22.CrossRefPubMed
9.
Zurück zum Zitat Klotz S, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005;112(3):364–74.CrossRefPubMed Klotz S, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005;112(3):364–74.CrossRefPubMed
10.
Zurück zum Zitat Vatta M, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 2002;359(9310):936–41.CrossRefPubMed Vatta M, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 2002;359(9310):936–41.CrossRefPubMed
11.
Zurück zum Zitat Vatta M, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol. 2004;43(5):811–7.CrossRefPubMed Vatta M, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol. 2004;43(5):811–7.CrossRefPubMed
12.
Zurück zum Zitat Stetson SJ, et al. Improved myocardial structure following LVAD support: effect of unloading on dystrophin expression. J Heart Lung Transplant. 2001;20(2):240.CrossRefPubMed Stetson SJ, et al. Improved myocardial structure following LVAD support: effect of unloading on dystrophin expression. J Heart Lung Transplant. 2001;20(2):240.CrossRefPubMed
13.
Zurück zum Zitat Rodrigue-Way A, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant. 2005;24(1):73–80.CrossRefPubMed Rodrigue-Way A, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant. 2005;24(1):73–80.CrossRefPubMed
14.
Zurück zum Zitat de Jonge N, et al. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol. 2002;39(6):963–9.CrossRefPubMed de Jonge N, et al. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol. 2002;39(6):963–9.CrossRefPubMed
15.
Zurück zum Zitat Aquila LA, et al. Cytoskeletal structure and recovery in single human cardiac myocytes. J Heart Lung Transpl. 2004;23(8):954–63.CrossRef Aquila LA, et al. Cytoskeletal structure and recovery in single human cardiac myocytes. J Heart Lung Transpl. 2004;23(8):954–63.CrossRef
16.
Zurück zum Zitat Birks EJ, et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation. 2005;112(9 Suppl):I57–64.PubMed Birks EJ, et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation. 2005;112(9 Suppl):I57–64.PubMed
17.
Zurück zum Zitat Noguchi T, et al. Thin-filament-based modulation of contractile performance in human heart failure. Circulation. 2004;110(8):982–7.CrossRefPubMed Noguchi T, et al. Thin-filament-based modulation of contractile performance in human heart failure. Circulation. 2004;110(8):982–7.CrossRefPubMed
18.
Zurück zum Zitat Klotz S, et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol. 2007;49(11):1166–74.CrossRefPubMed Klotz S, et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol. 2007;49(11):1166–74.CrossRefPubMed
19.
Zurück zum Zitat Liang H, et al. Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy. Chin Med J (Engl). 2004;117(3):401–7. Liang H, et al. Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy. Chin Med J (Engl). 2004;117(3):401–7.
20.
Zurück zum Zitat Bruggink AH, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transpl. 2006;25(9):1091–8.CrossRef Bruggink AH, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transpl. 2006;25(9):1091–8.CrossRef
21.
Zurück zum Zitat Li YY, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation. 2001;104(10):1147–52.CrossRefPubMed Li YY, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation. 2001;104(10):1147–52.CrossRefPubMed
22.
Zurück zum Zitat Matsumiya G, et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg. 2005;130(3):699–704.CrossRefPubMed Matsumiya G, et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg. 2005;130(3):699–704.CrossRefPubMed
23.
Zurück zum Zitat McCarthy PM, et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg. 1995;59(3):609–13.CrossRefPubMed McCarthy PM, et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg. 1995;59(3):609–13.CrossRefPubMed
24.
Zurück zum Zitat Taketani S, et al. Myocardial histological changes in dilated cardiomyopathy during a long-term left ventricular assist device support. Heart Vessels. 1997;12(2):98–100.CrossRefPubMed Taketani S, et al. Myocardial histological changes in dilated cardiomyopathy during a long-term left ventricular assist device support. Heart Vessels. 1997;12(2):98–100.CrossRefPubMed
25.
Zurück zum Zitat Scheinin SA, et al. The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy. Asaio J. 1992;38(3):M271–4.CrossRefPubMed Scheinin SA, et al. The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy. Asaio J. 1992;38(3):M271–4.CrossRefPubMed
26.
Zurück zum Zitat Muller J, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997;96(2):542–9.CrossRefPubMed Muller J, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997;96(2):542–9.CrossRefPubMed
27.
Zurück zum Zitat Thompson LO, et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res. 2005;123(1):25–32.CrossRefPubMed Thompson LO, et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res. 2005;123(1):25–32.CrossRefPubMed
28.
Zurück zum Zitat Thohan V, et al. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transpl. 2005;24(5):566–75.CrossRef Thohan V, et al. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transpl. 2005;24(5):566–75.CrossRef
29.
Zurück zum Zitat Akgul A, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transpl. 2004;23(6):709–15.CrossRef Akgul A, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transpl. 2004;23(6):709–15.CrossRef
30.
Zurück zum Zitat Bruggink AH, et al. Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. Lab Invest. 2007;87(11):1125–37.CrossRefPubMed Bruggink AH, et al. Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. Lab Invest. 2007;87(11):1125–37.CrossRefPubMed
31.
32.
Zurück zum Zitat Moshal KS, et al. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med. 2005;9(3):704–13.CrossRefPubMed Moshal KS, et al. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med. 2005;9(3):704–13.CrossRefPubMed
33.
Zurück zum Zitat Jinga DC, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10(2):499–510.PubMedCentralCrossRefPubMed Jinga DC, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10(2):499–510.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Spinale FG, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46(2):225–38.CrossRefPubMed Spinale FG, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46(2):225–38.CrossRefPubMed
35.
Zurück zum Zitat Thomas CV, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97(17):1708–15.CrossRefPubMed Thomas CV, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97(17):1708–15.CrossRefPubMed
36.
Zurück zum Zitat Oh J, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107(6):789–800.CrossRefPubMed Oh J, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107(6):789–800.CrossRefPubMed
37.
38.
Zurück zum Zitat de Jonge N, et al. Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. J Heart Lung Transpl. 2003;22(9):1028–36.CrossRef de Jonge N, et al. Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. J Heart Lung Transpl. 2003;22(9):1028–36.CrossRef
39.
Zurück zum Zitat Francis GS, et al. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail. 1999;5(4):308–15.CrossRefPubMed Francis GS, et al. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail. 1999;5(4):308–15.CrossRefPubMed
40.
Zurück zum Zitat Patten RD, et al. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol. 2005;45(9):1419–24.CrossRefPubMed Patten RD, et al. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol. 2005;45(9):1419–24.CrossRefPubMed
41.
Zurück zum Zitat Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994;105(3):897–904.CrossRefPubMed Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994;105(3):897–904.CrossRefPubMed
42.
Zurück zum Zitat Kubota T, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81(4):627–35.CrossRefPubMed Kubota T, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81(4):627–35.CrossRefPubMed
43.
Zurück zum Zitat Torre-Amione G, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201–6.CrossRefPubMed Torre-Amione G, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201–6.CrossRefPubMed
44.
Zurück zum Zitat Torre-Amione G, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : a potential mechanism for cardiac recovery. Circulation. 1999;100(11):1189–93.CrossRefPubMed Torre-Amione G, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : a potential mechanism for cardiac recovery. Circulation. 1999;100(11):1189–93.CrossRefPubMed
45.
Zurück zum Zitat Bartling B, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999;100(19 Suppl):II216–23.PubMed Bartling B, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999;100(19 Suppl):II216–23.PubMed
46.
Zurück zum Zitat Wong SYC, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation. 1998;98:100–3.CrossRefPubMed Wong SYC, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation. 1998;98:100–3.CrossRefPubMed
47.
Zurück zum Zitat Grabellus F, et al. Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res. 2002;53(1):124–30.CrossRefPubMed Grabellus F, et al. Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res. 2002;53(1):124–30.CrossRefPubMed
48.
Zurück zum Zitat Baba HA, et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res. 2003;59(2):390–9.CrossRefPubMed Baba HA, et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res. 2003;59(2):390–9.CrossRefPubMed
49.
Zurück zum Zitat Flesch M, et al. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation. 2001;104(19):2273–6.CrossRefPubMed Flesch M, et al. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation. 2001;104(19):2273–6.CrossRefPubMed
50.
Zurück zum Zitat Hall JL, et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004;17(3):283–91.CrossRefPubMed Hall JL, et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004;17(3):283–91.CrossRefPubMed
51.
Zurück zum Zitat Dipla K, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97(23):2316–22.CrossRefPubMed Dipla K, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97(23):2316–22.CrossRefPubMed
52.
Zurück zum Zitat Milting H, et al. Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol. 2006;41(3):441–50.CrossRefPubMed Milting H, et al. Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol. 2006;41(3):441–50.CrossRefPubMed
53.
Zurück zum Zitat Kittleson MM, et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation. 2004;110(22):3444–51.CrossRefPubMed Kittleson MM, et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation. 2004;110(22):3444–51.CrossRefPubMed
54.
Zurück zum Zitat Chen Y, et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics. 2003;14(3):251–60.CrossRefPubMed Chen Y, et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics. 2003;14(3):251–60.CrossRefPubMed
55.
Zurück zum Zitat Jahanyar J, et al. Increased expression of stem cell factor and its receptor after left ventricular assist device support: a potential novel target for therapeutic interventions in heart failure. J Heart Lung Transpl. 2008;27(7):701–9.CrossRef Jahanyar J, et al. Increased expression of stem cell factor and its receptor after left ventricular assist device support: a potential novel target for therapeutic interventions in heart failure. J Heart Lung Transpl. 2008;27(7):701–9.CrossRef
56.
Zurück zum Zitat Deng MC, et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: second annual report—2004. J Heart Lung Transpl. 2004;23(9):1027–34.CrossRef Deng MC, et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: second annual report—2004. J Heart Lung Transpl. 2004;23(9):1027–34.CrossRef
57.
Zurück zum Zitat Rockman HA, et al. Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. Am Heart J. 1991;121(3 Pt 1):922–6.CrossRefPubMed Rockman HA, et al. Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. Am Heart J. 1991;121(3 Pt 1):922–6.CrossRefPubMed
58.
Zurück zum Zitat Levin HR, et al. Transient normalization of systolic and diastolic function after support with a left ventricular assist device in a patient with dilated cardiomyopathy. J Heart Lung Transpl. 1996;15(8):840–2. Levin HR, et al. Transient normalization of systolic and diastolic function after support with a left ventricular assist device in a patient with dilated cardiomyopathy. J Heart Lung Transpl. 1996;15(8):840–2.
59.
Zurück zum Zitat Helman DN, et al. Recurrent remodeling after ventricular assistance: is long-term myocardial recovery attainable? Ann Thorac Surg. 2000;70(4):1255–8.CrossRefPubMed Helman DN, et al. Recurrent remodeling after ventricular assistance: is long-term myocardial recovery attainable? Ann Thorac Surg. 2000;70(4):1255–8.CrossRefPubMed
60.
Zurück zum Zitat Mancini DM, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98(22):2383–9.CrossRefPubMed Mancini DM, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98(22):2383–9.CrossRefPubMed
61.
Zurück zum Zitat El-Banayosy A, et al. Hemodynamic exercise testing reveals a low incidence of myocardial recovery in LVAD patients. J Heart Lung Transpl. 2001;20(2):209–10.CrossRef El-Banayosy A, et al. Hemodynamic exercise testing reveals a low incidence of myocardial recovery in LVAD patients. J Heart Lung Transpl. 2001;20(2):209–10.CrossRef
62.
Zurück zum Zitat Liden H, et al. The feasibility of left ventricular mechanical support as a bridge to cardiac recovery. Eur J Heart Fail. 2007;9(5):525–30.CrossRefPubMed Liden H, et al. The feasibility of left ventricular mechanical support as a bridge to cardiac recovery. Eur J Heart Fail. 2007;9(5):525–30.CrossRefPubMed
63.
Zurück zum Zitat Farrar DJ, et al. Long-term follow-up of thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transpl. 2002;21(5):516–21.CrossRef Farrar DJ, et al. Long-term follow-up of thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transpl. 2002;21(5):516–21.CrossRef
64.
Zurück zum Zitat Grinda JM, et al. Fulminant myocarditis in adults and children: bi-ventricular assist device for recovery. Eur J Cardiothorac Surg. 2004;26(6):1169–73.CrossRefPubMed Grinda JM, et al. Fulminant myocarditis in adults and children: bi-ventricular assist device for recovery. Eur J Cardiothorac Surg. 2004;26(6):1169–73.CrossRefPubMed
65.
Zurück zum Zitat Hoy FB, et al. Bridge to recovery for postcardiotomy failure: is there still a role for centrifugal pumps? Ann Thorac Surg. 2000;70(4):1259–63.CrossRefPubMed Hoy FB, et al. Bridge to recovery for postcardiotomy failure: is there still a role for centrifugal pumps? Ann Thorac Surg. 2000;70(4):1259–63.CrossRefPubMed
66.
Zurück zum Zitat Birks EJ, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873–84.CrossRefPubMed Birks EJ, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873–84.CrossRefPubMed
67.
Zurück zum Zitat Barton PJ, et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation. 2005;112(9 Suppl):I46–50.PubMed Barton PJ, et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation. 2005;112(9 Suppl):I46–50.PubMed
68.
Zurück zum Zitat Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg. 2003;75(6 Suppl):S36–41.CrossRefPubMed Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg. 2003;75(6 Suppl):S36–41.CrossRefPubMed
69.
Zurück zum Zitat George I, et al. Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transpl. 2006;25(9):1084–90.CrossRef George I, et al. Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transpl. 2006;25(9):1084–90.CrossRef
70.
Zurück zum Zitat Maybaum S, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115(19):2497–505.CrossRefPubMed Maybaum S, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115(19):2497–505.CrossRefPubMed
71.
Zurück zum Zitat Khan T, et al. Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. J Heart Lung Transpl. 2003;22(2):137–46.CrossRef Khan T, et al. Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. J Heart Lung Transpl. 2003;22(2):137–46.CrossRef
72.
Zurück zum Zitat Miyagawa S, et al. Analysis of sympathetic nerve activity in end-stage cardiomyopathy patients receiving left ventricular support. J Heart Lung Transpl. 2001;20(11):1181–7.CrossRef Miyagawa S, et al. Analysis of sympathetic nerve activity in end-stage cardiomyopathy patients receiving left ventricular support. J Heart Lung Transpl. 2001;20(11):1181–7.CrossRef
73.
Zurück zum Zitat Bruckner BA, et al. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transpl. 2004;23(1):36–42.CrossRef Bruckner BA, et al. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transpl. 2004;23(1):36–42.CrossRef
74.
Zurück zum Zitat Tijsen AJ, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9.CrossRefPubMed Tijsen AJ, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9.CrossRefPubMed
Metadaten
Titel
Building a bridge to recovery: the pathophysiology of LVAD-induced reverse modeling in heart failure
verfasst von
Shigeru Miyagawa
Koichi Toda
Teruya Nakamura
Yasushi Yoshikawa
Satsuki Fukushima
Shunsuke Saito
Daisuke Yoshioka
Tetsuya Saito
Yoshiki Sawa
Publikationsdatum
01.02.2016
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 2/2016
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-015-1149-8

Weitere Artikel der Ausgabe 2/2016

Surgery Today 2/2016 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Metformin rückt in den Hintergrund

24.04.2024 DGIM 2024 Kongressbericht

Es hat sich über Jahrzehnte klinisch bewährt. Doch wo harte Endpunkte zählen, ist Metformin als alleinige Erstlinientherapie nicht mehr zeitgemäß.

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

24.04.2024 DGIM 2024 Kongressbericht

Unerkannte Herzmuskelentzündungen infolge einer Virusinfektion führen immer wieder dazu, dass junge, gesunde Menschen plötzlich beim Sport einen Herzstillstand bekommen. Gerade milde Herzbeteiligungen sind oft schwer zu diagnostizieren – speziell bei Leistungssportlern. 

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.